This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Gadolinium
DrugBank Accession Number
DB12091
Background

Gadolinium is under investigation in Hypertension, ACUTE KIDNEY INJURY, and Chronic Kidney Disease. Gadolinium has been investigated for the basic science of CAD, Multiple Sclerosis, and Coronary Artery Disease.

Type
Small Molecule
Groups
Approved, Investigational
Structure
Thumb
Weight
Average: 157.25
Monoisotopic: 157.924100533
Chemical Formula
Gd
Synonyms
  • gadolinio

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Gadolinium ChlorideP7082WY76D10138-52-0MEANOSLIBWSCIT-UHFFFAOYSA-K

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of inorganic compounds known as homogeneous lanthanide compounds. These are inorganic compounds containing only metal atoms, with the largest atom being a lanthanide atom.
Kingdom
Inorganic compounds
Super Class
Homogeneous metal compounds
Class
Homogeneous lanthanide compounds
Sub Class
Not Available
Direct Parent
Homogeneous lanthanide compounds
Alternative Parents
Not Available
Substituents
Homogeneous lanthanide
Molecular Framework
Not Available
External Descriptors
lanthanoid atom, f-block element atom (CHEBI:33375)
Affected organisms
Not Available

Chemical Identifiers

UNII
AU0V1LM3JT
CAS number
7440-54-2
InChI Key
UIWYJDYFSGRHKR-UHFFFAOYSA-N
InChI
InChI=1S/Gd
IUPAC Name
gadolinium
SMILES
[Gd]

References

General References
Not Available
Human Metabolome Database
HMDB0041899
PubChem Compound
23982
PubChem Substance
347828395
ChemSpider
22418
RxNav
1310171
ChEBI
33375
PDBe Ligand
GD
Wikipedia
Gadolinium
PDB Entries
1b9x / 1b9y / 1h87 / 1ima / 1imb / 1isr / 1v8m / 2hhm / 2p80 / 2trc
show 84 more

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedDiagnosticAcute Graft Rejection / Cardiac Transplant / Chronic Graft Rejection1
4CompletedTreatmentHip Fracture / Local anesthesia therapy / Postoperative pain1
4RecruitingScreeningCirrhosis of the Liver / Hepatocellular Carcinoma / Liver Cancer1
4TerminatedDiagnosticMenière's Disease1
4WithdrawnDiagnosticContrast Media Allergy1
4WithdrawnDiagnosticPulmonary Embolism1
2CompletedTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
2Not Yet RecruitingTreatmentAGuIX / Breast Cancer / Cancer Brain / Colorectal Carcinoma (CRC) / Cystic / Gastrointestinal Cancers / HER2/Neu-positive Breast Cancer / Lung Cancers / Malignant Melanoma of Skin / Nanoparticles / Neoplasms, Brain / SRS / SRT / Stereotactic Radiation / Tumors Metastatic to Brain / Whole Brain Radiation1
2RecruitingBasic ScienceTraumatic Brain Injury (TBI)1
2RecruitingDiagnosticBrain Neoplasms, Primary / Metastatic Malignant Neoplasm in the Brain1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
logP0ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count0ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area0 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity0 m3·mol-1ChemAxon
Polarizability1.78 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created at October 20, 2016 21:20 / Updated at June 12, 2020 16:53